Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Wen Kong, Guangyu Wu, Yunze Xu, Zaoyu Wang, Jin Zhang
Institutions: Shanghai Jiao Tong University, Renji Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407678331